Dr. Ruben Mesa on COMFORT-I for Myelofibrosis

Ruben Mesa, MD
Published: Friday, Jun 10, 2016



Ruben Mesa, MD chair, hematology Mayo Clinic, discusses the longterm data from COMFORT-I, a randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of ruxolitinib compared with placebo in patients with intermediate-2 and high-risk myelofibrosis.
 
In the 5-year analysis, patients continued to see improvements in symptoms and in splenomegaly with ruxolitinib, says Mesa.
 
Fifty-nine percent (92/155) of patients originally randomized to ruxolitinib remained on the study and had a ≥35% spleen volume response at any time on study.
 
The life expectancy of the patients enrolled in this study was under 3 years or less, so the fact that so many remain on the study further demonstrates the significant benefit of ruxolitinib, says Mesa.
 
There was a clear survival advantage with ruxolitinib compared to the control arm, with median overall survival (OS) not yet reached for patients receiving ruxolitinib and 200 weeks for patients in the placebo arm.

<<< View more from the 2016 EHA Congress


Ruben Mesa, MD chair, hematology Mayo Clinic, discusses the longterm data from COMFORT-I, a randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of ruxolitinib compared with placebo in patients with intermediate-2 and high-risk myelofibrosis.
 
In the 5-year analysis, patients continued to see improvements in symptoms and in splenomegaly with ruxolitinib, says Mesa.
 
Fifty-nine percent (92/155) of patients originally randomized to ruxolitinib remained on the study and had a ≥35% spleen volume response at any time on study.
 
The life expectancy of the patients enrolled in this study was under 3 years or less, so the fact that so many remain on the study further demonstrates the significant benefit of ruxolitinib, says Mesa.
 
There was a clear survival advantage with ruxolitinib compared to the control arm, with median overall survival (OS) not yet reached for patients receiving ruxolitinib and 200 weeks for patients in the placebo arm.

<<< View more from the 2016 EHA Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x